15

20

25

## A-665B

## What is claimed is:

1. A composition of matter of the formula

P1-(L1),-F1

and multimers thereof, wherein:

F<sup>1</sup> is a vehicle and is attached at the C-terminus of P<sup>1</sup>-(L<sup>1</sup>),
P<sup>1</sup> is a PTH/PTHrP modulating domain;

L1 is a linker; and

a is 0 or 1.

2. The composition of matter of Claim 1 of the formulae

P1-F1.

- 3. The composition of matter of Claim 1, wherein F<sup>1</sup> is an Fc domain.
- The composition of matter of Claim 1 wherein F¹ is an IgG Fc domain.
- 5. The composition of matter of Claim 1 wherein  $F^{l}$  is an IgG1 Fc domain.
- The composition of matter of Claim 1 wherein F<sup>1</sup> comprises the sequence of SEQ ID NO: 2.
- The composition of matter of Claim 1 wherein the PTH/PTHrP modulating domain is of the formula

 $X^{N}HX^{10}X^{11}X^{12}KX^{14}X^{15}X^{16}X^{17}X^{18}X^{19}RX^{21}X^{22}X^{23}X^{24}X^{25}X^{26}X^{27}X^{28}X^{c}$ (SEO ID NO: 3)

wherein:

 $X^N$  is absent or is  $X^3X^4X^3X^6X^7$ ,  $X^2X^3X^4X^5X^6X^7$ ,  $X^1X^2X^3X^4X^5X^6X^7$ , or  $YX^1X^2X^3X^4X^5X^6X^7$ ;

 $X^1$  through  $X^7$ ,  $X^{10}$ ,  $X^{11}$ ,  $X^{12}$ ,  $X^{14}$  through  $X^{28}$  are each independently amino acid residues;

 $X^c$  is absent or is  $X^{29}$ ,  $X^{29}X^{10}$ ,  $X^{29}X^{20}X^{11}$ ,  $X^{22}X^{20}X^{11}X^{12}$ ,  $X^{22}X^{20}X^{21}X^{22}X^{23}$ ,  $X^{22}X^{20}X^{21}X^{22}X^{23}$ ,  $X^{22}X^{20}X^{21}X^{22}X^{23}X^{24}X^{25}$ , or  $X^{29}X^{20}X^{21}X^{22}X^{23}X^{24}X^{25}$ .

X<sup>29</sup> through X<sup>36</sup> are each independently amino acid residues.

8. The composition of matter of Claim 7, wherein:

 $X^{N}$  is  $X^{1}X^{2}X^{3}X^{4}X^{5}X^{6}X^{7}$ :

X1 is a hydrophilic or nonfunctional residue;

5 X<sup>2</sup> is V:

X3 is S:

X4 is E:

X<sup>5</sup> is a nonfunctional or basic residue:

X6 is Q;

10 X<sup>7</sup> is L;

X10 is an acidic or hydrophilic residue;

X<sup>11</sup> is a nonfunctional or basic residue;

X12 is a nonfunctional residue;

X14 is a basic or hydrophilic residue;

X15 is a nonfunctional residue:

X<sup>16</sup> is a nonfunctional or hydrophilic residue;

X<sup>17</sup> is an acidic, hydrophilic, or nonfunctional residue;

X18 is a nonfunctional residue:

X19 is an acidic or basic residue:

20 X<sup>21</sup> is a nonfunctional or basic residue;

X<sup>22</sup> is a hydrophilic, acidic, or aromatic residue;

X<sup>23</sup> is an aromatic or lipophilic residue;

 $X^{24}$  is a lipophilic residue (L preferred);

X<sup>25</sup> is a hydrophilic or basic residue;

25 X<sup>26</sup> is a hydrophilic or basic residue;

X<sup>27</sup> is a lipophilic, basic, or nonfunctional residue; and

X<sup>28</sup> is a lipophilic or nonfunctional residue.

9. The composition of matter of Claim 8, wherein:

 $X^{C}$  is  $X^{29}X^{30}X^{31}X^{32}X^{33}X^{34}$ ;

10

15

25

X<sup>29</sup> is a hydrophilic or nonfunctional residue;

X<sup>30</sup> is a hydrophilic or acidic residue;

X<sup>31</sup> is a lipophilic or nonfunctional residue;

X32 is H;

X33 is a hydrophilic residue; and

X34 is a nonfunctional or aromatic residue.

10. The composition of matter of Claim 8, wherein:

 $X^{C}$  is  $X^{29}X^{30}X^{31}$ :

X<sup>29</sup> is a hydrophilic or nonfunctional residue;

X<sup>30</sup> is a hydrophilic or acidic residue; and

 $X^{31}$  is a lipophilic or nonfunctional residue.

11. The composition of matter of Claim 8, wherein:

 $X^{C}$  is  $X^{29}X^{30}$ ;

 $\boldsymbol{X}^{\!\scriptscriptstyle 29}$  is a hydrophilic or nonfunctional residue; and

X<sup>30</sup> is a hydrophilic or acidic residue.

12. The composition of matter of Claim 8, wherein:

X<sup>C</sup> is X<sup>29</sup>; and

X<sup>29</sup> is a hydrophilic or nonfunctional residue.

- 13. The composition of matter of Claim 8, wherein  $X^c$  is absent.
- 20 14. The composition of matter of Claim 8, wherein:

X1 is A. S or Y:

X5 is H or I:

X10 is N or D:

X11 is L, R, or K;

X12 is G. F. or W:

X14 is H or S:

X15 is L or I;

X16 is O. N. S. or A:

X17 is S, D, or L;

25

X18 is M. L. V or NIe:

X19 is E or R:

X21 is V. M. R. or Nle:

X22 is E or F;

5 X<sup>23</sup> is W or F;

X25 is R or H;

X26 is K or H;

X27 is K or L: and

X28 is L or I.

10 15. The composition of matter of Claim 14, wherein:

 $X^{\scriptscriptstyle C} \text{ is } X^{\scriptscriptstyle 29} X^{\scriptscriptstyle 30} X^{\scriptscriptstyle 31} X^{\scriptscriptstyle 32} X^{\scriptscriptstyle 33} X^{\scriptscriptstyle 34};$ 

 $X^{29}$  is Q or A;

 $X^{30}$  is D or E;

X31 is V or I;

X33 is N or T: and

 $X^{34}$  is A, F or Y.

16. The composition of matter of Claim 14, wherein:

 $X^{C}$  is  $X^{29}X^{30}X^{31}$ ;

X29 is O or A;

20 X<sup>30</sup> is D or E; and

X31 is V or I:

17. The composition of matter of Claim 14, wherein:

X<sup>C</sup> is X<sup>29</sup>X<sup>30</sup>;

X29 is O or A; and

X30 is D or E.

18. The composition of matter of Claim 14, wherein:

X<sup>C</sup> is X<sup>29</sup>; and

X<sup>29</sup> is O or A.

19. The composition of matter of Claim 14, wherein  $X^c$  is absent.

15

2.0

25

 The composition of matter of Claim 1, wherein the PTH/PTHrP modulating domain is of the formula

J<sup>N</sup>J<sup>7</sup>J<sup>8</sup>HNJ<sup>11</sup>J<sup>12</sup>KHLJ<sup>16</sup>SJ<sup>18</sup>J<sup>19</sup>RJ<sup>21</sup>EWLRKKLJ<sup>C</sup>
(SEO ID NO: 4)

5 wherein:

I<sup>N</sup> is absent or is selected from [<sup>1</sup>T<sup>2</sup>T<sup>3</sup>T<sup>4</sup>T<sup>5</sup>J<sup>6</sup>, [<sup>2</sup>T<sup>3</sup>T<sup>4</sup>J<sup>5</sup>J<sup>6</sup>, [<sup>3</sup>T<sup>4</sup>J<sup>5</sup>J<sup>6</sup>;

J1 is an amino acid residue;

I<sup>2</sup> is an amino acid residue;

I3 is an amino acid residue;

I4 is an amino acid residue;

I5 is an amino acid residue;

I6 is an amino acid residue:

I' is an amino acid residue;

Is an amino acid residue;

In is a nonfunctional or basic residue;

I12 is an amino acid residue;

I16 is an amino acid residue;

I18 is an amino acid residue;

I19 is an acidic or basic residue;

I21 is an amino acid residue:

 $I^{C}$  is absent or is  $I^{29}$ ,  $I^{29}I^{30}$ ,  $I^{29}I^{30}I^{31}$ ,  $I^{29}I^{30}I^{31}I^{32}$ ,  $I^{29}I^{30}I^{31}I^{32}$ ,

I29I30I31I32I33I34; and

J<sup>29</sup> is an amino acid residue;

I<sup>30</sup> is an amino acid residue:

I31 is an amino acid residue;

I<sup>32</sup> is an amino acid residue:

I<sup>33</sup> is an amino acid residue;

I<sup>34</sup> is an amino acid residue.

21. The composition of matter of Claim 20, wherein:

10

15

20

25

22.

 $J^5$  is I;  $I^6$  is O;

```
I<sup>N</sup> is I<sup>1</sup>I<sup>2</sup>I<sup>3</sup>I<sup>4</sup>I<sup>5</sup>I<sup>6</sup>;
       I<sup>1</sup> is a nonfunctional or aromatic residue;
       I2 is a nonfunctional residue;
       I3 is a hydrophilic residue;
       J⁴ is an acidic residue;
       I<sup>5</sup> is a nonfunctional residue;
       I6 is a basic residue;
       I' is a nonfunctional or aromatic residue;
        I8 is a nonfunctional residue;
        In is a basic or a nonfunctional residue;
        I12 is a nonfunctional or aromatic residue;
        I16 is a nonfunctional or hydrophilic residue;
        I18 is a nonfunctional residue;
        I19 is an acidic or basic residue; and
        I21 is a nonfunctional residue;
        I^{C} is I^{29}I^{30}I^{31}I^{32}I^{33}I^{34};
        J<sup>29</sup> is a hydrophilic or nonfunctional residue;
        J<sup>30</sup> is a hydrophilic or acidic residue;
        I<sup>31</sup> is a lipophilic or nonfunctional residue;
        J32 is a basic residue;
        I33 is an acidic residue; and
        I<sup>34</sup> is an aromatic residue.
The composition of matter of Claim 21, wherein:
        J1 is A, S or Y;
        I2 is V;
        I3 is S:
        J4 is E;
```

```
I' is L or F:
                      I<sup>8</sup> is M or Nle;
                      I11 is L, R, or K:
                      I12 is G or W;
                      I16 is N, S, or A;
5
                      I18 is M. Nle. L. or V:
                       I19 is E or R;
                      I21 is V, M, or Nle;
                      J<sup>29</sup> is Q or A;
                      I<sup>30</sup> is D or E:
10
                       I31 is V or I;
                       I32 is H;
                       I33 is N: and
                       I<sup>34</sup> is F or Y.
              The composition of matter of Claim 20, wherein:
15
      23.
                       J^{N} is J^{1}J^{2}J^{3}J^{4}J^{5}J^{6};
                       I1 is a nonfunctional or aromatic residue;
                       I<sup>2</sup> is a nonfunctional residue;
                       I3 is a hydrophilic residue;
                       I4 is an acidic residue;
20
                       I<sup>5</sup> is a nonfunctional residue;
                       I6 is a basic residue;
                       I' is a nonfunctional or aromatic residue;
                       I<sup>8</sup> is a nonfunctional residue;
                       I" is a basic or a nonfunctional residue;
25
                        I12 is a nonfunctional or aromatic residue;
                        I16 is a nonfunctional or hydrophilic residue;
                        I18 is a nonfunctional residue;
```

I19 is an acidic or basic residue;

10

15

20

25

```
I21 is a nonfunctional residue;
```

J<sup>C</sup> is J<sup>29</sup>J<sup>30</sup>J<sup>31</sup>;

J29 is a hydrophilic or nonfunctional residue;

J<sup>30</sup> is a hydrophilic or acidic residue; and

I<sup>31</sup> is a lipophilic or nonfunctional residue.

24. The composition of matter of Claim 23, wherein:

J1 is A, S or Y;

I2 is V:

J<sup>3</sup> is S;

J4 is E;

J<sup>5</sup> is I;

J<sup>6</sup> is Q; J<sup>7</sup> is L or F:

J IS L OI I,

J<sup>8</sup> is M or Nle;

 $J^{11}$  is L, R, or K;

J12 is G or W;

J16 is N, S, or A;

I18 is M. Nle, L, or V;

I19 is E or R;

J21 is V, M, or Nle;

I29 is O or A:

I30 is D or E; and

 $I^{31}$  is V or I.

25. The composition of matter of Claim 20, wherein:

 $I^{N}$  is  $I^{1}I^{2}I^{3}I^{4}I^{5}I^{6}$ ;

I1 is a nonfunctional or aromatic residue;

J2 is a nonfunctional residue;

J<sup>3</sup> is a hydrophilic residue;

I4 is an acidic residue;

10

15

25

```
J<sup>5</sup> is a nonfunctional residue;
J<sup>6</sup> is a basic residue;
J<sup>7</sup> is a nonfunctional or aromatic residue;
J<sup>8</sup> is a nonfunctional residue;
J<sup>11</sup> is a basic or a nonfunctional residue;
```

J<sup>12</sup> is a nonfunctional or aromatic residue;

 $J^{^{16}}$  is a nonfunctional or hydrophilic residue;

 $J^{18}$  is a nonfunctional residue;

J<sup>19</sup> is an acidic or basic residue;

 $J^{21}$  is a nonfunctional residue;

J<sup>c</sup> is J<sup>29</sup>J<sup>30</sup>;

J<sup>29</sup> is a hydrophilic or nonfunctional residue; and

I<sup>30</sup> is a hydrophilic or acidic residue.

26. The composition of matter of Claim 25, wherein:

J is A, S or Y;

I2 is V;

J³ is S;

J4 is E;

J<sup>5</sup> is I;

20 J<sup>6</sup> is Q;

I' is L or F;

J<sup>8</sup> is M or Nle;

J11 is L, R, or K;

I12 is G or W;

J16 is N, S, or A;

J18 is M, Nle, L, or V;

J19 is E or R;

J21 is V, M, or Nle;

 $J^{29}$  is Q or A; and

10

15

25

## I<sup>30</sup> is D or E.

27. The composition of matter of Claim 20, wherein:

 $J^{N}$  is  $J^{1}J^{2}J^{3}J^{4}J^{5}J^{6}$ ;

J¹ is a nonfunctional or aromatic residue;

I<sup>2</sup> is a nonfunctional residue;

J<sup>3</sup> is a hydrophilic residue;

J' is an acidic residue;

J5 is a nonfunctional residue;

I6 is a basic residue;

I' is a nonfunctional or aromatic residue;

I8 is a nonfunctional residue;

In is a basic or a nonfunctional residue;

I12 is a nonfunctional or aromatic residue;

I<sup>16</sup> is a nonfunctional or hydrophilic residue;

I18 is a nonfunctional residue;

I19 is an acidic or basic residue;

I21 is a nonfunctional residue;

I<sup>c</sup> is I<sup>29</sup>; and

J<sup>29</sup> is a hydrophilic or nonfunctional residue.

20 28. The composition of matter of Claim 27, wherein:

I1 is A. S or Y:

 $J^{2}$  is V;

I3 is S:

I4 is E:

I<sup>5</sup> is I:

I6 is O:

I' is L or F:

J<sup>8</sup> is M or Nle;

J11 is L, R, or K;

29.

5

10

15

20

25

30.

I<sup>5</sup> is I;

```
I12 is G or W:
       I16 is N.S. or A:
       I18 is M. Nle, L, or V;
       I19 is E or R:
       I21 is V, M, or Nle; and
       I29 is O or A.
The composition of matter of Claim 20, wherein:
       J^{N} is J^{1}J^{2}J^{3}J^{4}J^{5}J^{6};
       I1 is a nonfunctional or aromatic residue;
       I2 is a nonfunctional residue;
       J<sup>3</sup> is a hydrophilic residue;
       J<sup>4</sup> is an acidic residue;
        I5 is a nonfunctional residue;
        I6 is a basic residue;
        J' is a nonfunctional or aromatic residue;
        I8 is a nonfunctional residue;
        In is a basic or a nonfunctional residue;
        J12 is a nonfunctional or aromatic residue;
        I<sup>16</sup> is a nonfunctional or hydrophilic residue;
        I18 is a nonfunctional residue;
        I19 is an acidic or basic residue;
        I21 is a nonfunctional residue; and
        J^{c} is absent.
The composition of matter of Claim 29, wherein:
        J1 is A, S or Y;
        I2 is V;
        J3 is S;
        I is E:
```

15

20

25

J<sup>6</sup> is Q;
J<sup>7</sup> is L or F;
J<sup>8</sup> is M or Nle;
J<sup>11</sup> is L, R, or K;
J<sup>12</sup> is G or W;
J<sup>16</sup> is N, S, or A;
J<sup>18</sup> is M, Nle, L, or V;

J<sup>19</sup> is E or R; and J<sup>21</sup> is V, M, or Nle.

- 10 31. The composition of matter of Claim 20, wherein the PTH/PTHrP modulating domain is selected from Table 1.
  - The composition of matter of Claim 1 wherein the PTH/PTHrP modulating domain is of the formula

O<sup>N</sup>LHO<sup>16</sup>O<sup>11</sup>O<sup>12</sup>KSIO<sup>16</sup>O<sup>17</sup>LRRRFO<sup>23</sup>LHHLIO<sup>C</sup> (SEQ ID NO: 5)

wherein:

O1 is an amino acid residue;

O2 is an amino acid residue;

O3 is an amino acid residue:

O4 is an amino acid residue:

O5 is an amino acid residue;

O6 is an amino acid residue;

O7 is an amino acid residue:

O10 is an amino acid residue;

O11 is an amino acid residue;

O12 is an amino acid residue;

10

15

20

25

O16 is an amino acid residue;

O17 is an amino acid residue:

O23 is an amino acid residue;

$$\begin{array}{c} O^{C} \text{ is absent or is } O^{29}, \, O^{29}O^{30}, \, O^{29}O^{30}O^{31}, \, O^{20}O^{30}O^{31}O^{32}, \\ \\ O^{29}O^{30}O^{31}O^{32}O^{33}, \, O^{29}O^{30}O^{31}O^{32}O^{33}O^{34} \, , \, O^{29}O^{30}O^{31}O^{32}O^{33}O^{34}O^{35}, \end{array}$$

or  $O^{29}O^{30}O^{31}O^{32}O^{33}O^{34}O^{35}O^{36}$ ; and

O29 through O36 are each independently amino acid residues.

33. The composition of matter of Claim 27, wherein:

 $O^N$  is  $O^7$ :

O7 is a nonfunctional residue:

O10 is an acidic or hydrophilic residue;

O11 is a basic or nonfunctional residue;

O12 is an aromatic or nonfunctional residue;

O15 is a hydrophilic or nonfunctional residue;

O16 is a hydrophilic residue;

O17 is an acidic or nonfunctional residue:

O23 is an aromatic residue; and

Oc is absent.

34. The composition of matter of Claim 23, wherein:

O<sup>N</sup> is O<sup>1</sup>O<sup>2</sup>O<sup>3</sup>O<sup>4</sup>O<sup>5</sup>O<sup>6</sup>O<sup>7</sup>:

O1 is a nonfunctional amino acid residue:

O2 is a nonfunctional amino acid residue;

O<sup>3</sup> is a hydrophilic amino acid residue;

O4 is an acidic amino acid residue:

O5 is a basic or nonfunctional amino acid residue;

O6 is a hydrophilic amino acid residue;

O<sup>7</sup> is a nonfunctional residue:

O10 is an acidic or hydrophilic residue;

O11 is a basic or nonfunctional residue;

10

15

- $O^{12}$  is an aromatic or nonfunctional residue;  $O^{15}$  is a hydrophilic or nonfunctional residue;
- O16 is a hydrophilic residue; and
- O17 is an acidic or nonfunctional residue; and
- O<sup>23</sup> is an aromatic residue.
- 35. The composition of matter of Claim 34, wherein:
  - O1 is A;
  - O2 is V:
  - O3 is S:
  - O4 is E:
  - O5 is H or I:
  - O6 is O:
  - $O^7$  is L:
  - O10 is N or D:
  - O11 is K or L:
  - O12 is G, F, or W;
  - O15 is I or S:
  - O16 is Q or N;
  - O17 is D or L:
- $O^{23}$  is F or W.
  - The composition of matter of Claim 27, wherein the PTH/PTHrP modulating domain is selected from Table 2.
  - The composition of matter of Claim 1, wherein the PTH/PTHrP modulating domain has the amino acid sequence of TIP39.
- 25 38. The composition of matter of Claim 1, comprising a sequence selected from Table 4.
  - A composition of matter, which comprises a peptide selected from SEQ ID NOS: 17, 18, 19, and 69.
  - A nucleic acid encoding a composition of matter of Claim 1.

- 41. A nucleic acid encoding a composition of matter of Claim 7.
- 42. A nucleic acid encoding a composition of matter of Claim 20.
- 43. A nucleic acid encoding a composition of matter of Claim 32.
- 44. A nucleic acid encoding a composition of matter of Claim 39.
- 5 45. An expression vector comprising the DNA of Claim 40.
  - 46. An expression vector comprising the DNA of Claim 41.
  - An expression vector comprising the DNA of Claim 42.
  - 48. An expression vector comprising the DNA of Claim 43.
  - 49. An expression vector comprising the DNA of Claim 44.
  - A host cell comprising the expression vector of Claim 45.
    - 51. A host cell comprising the expression vector of Claim 46.
    - 52. A host cell comprising the expression vector of Claim 47.
    - 53. A host cell comprising the expression vector of Claim 48.
    - 54. A host cell comprising the expression vector of Claim 49.
  - 55. The cell of Claim 50, wherein the cell is an E. coli cell.
    - 56. The cell of Claim 51, wherein the cell is an <u>E. coli</u> cell.
    - 57. The cell of Claim 52, wherein the cell is an E. coli cell.
    - 58. The cell of Claim 53, wherein the cell is an E. coli cell.
- 59. A process for preparing an antagonist of the PTH/PTHrP receptor,which comprises:
  - a) selecting at least one peptide that binds to the receptor; and
  - b) preparing a pharmacologic agent comprising at least one Fc domain covalently linked to at least one amino acid sequence of the selected peptide or peptides.
- 25 60. The process of Claim 59, wherein the peptide is selected from the SEQ ID NOS: 3, 4, or 5.
  - The process of Claim 59, wherein the peptide is selected in a process comprising screening of a phage display library, an <u>E. coli</u>

10

15

- display library, a ribosomal library, an RNA-peptide library, or a chemical peptide library.
- 62. The process of Claim 59, wherein the preparation of the pharmacologic agent is carried out by:
  - a) preparing a gene construct comprising a nucleic acid sequence encoding the selected peptide and a nucleic acid sequence encoding an Fc domain; and
  - b) expressing the gene construct.
- The process of Claim 59, wherein the gene construct is expressed in an E. coli cell.
- 64. The process of Claim 59, wherein the selection of the peptide is carried out by a process comprising:
  - a) preparing a gene construct comprising a nucleic acid sequence encoding a first selected peptide and a nucleic acid sequence encoding an Fc domain;
  - conducting a polymerase chain reaction using the gene construct and mutagenic primers, wherein
    - a first mutagenic primer comprises a nucleic acid sequence complementary to a sequence at or near the 5' end of a coding strand of the gene construct, and
    - ii) a second mutagenic primer comprises a nucleic acid sequence complementary to the 3' end of the noncoding strand of the gene construct.
- 65. A method of treating osteopenia, which comprises administering a
  25 PTH agonist and a bone resorption inhibitor, wherein the PTH
  agonist comprises a composition of matter of Claim 1.
  - 66. A method of treating osteopenia, which comprises administering a PTH agonist and a bone resorption inhibitor, wherein the PTH agonist comprises a composition of matter of Claim 7.

- 67. A method of treating osteopenia, which comprises administering a PTH agonist and a bone resorption inhibitor, wherein the PTH agonist comprises a composition of matter of Claim 20.
- 68. A method of treating osteopenia, which comprises administering a 5 PTH agonist and a bone resorption inhibitor, wherein the PTH agonist comprises a composition of matter of Claim 32.
  - 69. A method of treating osteopenia, which comprises administering a PTH agonist and a bone resorption inhibitor, wherein the PTH agonist comprises a composition of matter of Claim 39.
- The method of Claim 65, wherein the bone resorption inhibitor is selected from OPG, OPG-L antibody, calcitonin, bisphosphonates, estrogens, estrogen receptor modulators, and tibolone.
  - The method of Claim 66, wherein the bone resorption inhibitor is selected from OPG, OPG-L antibody, calcitonin, bisphosphonates, estrogens, estrogen receptor modulators, and tibolone.
  - 72. The method of Claim 67, wherein the bone resorption inhibitor is selected from OPG, OPG-L antibody, calcitonin, bisphosphonates, estrogens, estrogen receptor modulators, and tibolone.
- 73. The method of Claim 68, wherein the bone resorption inhibitor is
  20 selected from OPG, OPG-L antibody, calcitonin, bisphosphonates,
  estrogens, estrogen receptor modulators, and tibolone.
  - The method of Claim 69, wherein the bone resorption inhibitor is selected from OPG, OPG-L antibody, calcitonin, bisphosphonates, estrogens, estrogen receptor modulators, and tibolone.
- 25 75. A method of treating osteopenia, which comprises administering a composition of matter of Claim 1.
  - A method of treating osteopenia, which comprises administering a composition of matter of Claim 7.

## A-665B

- A method of treating osteopenia, which comprises administering a composition of matter of Claim 20.
- A method of treating osteopenia, which comprises administering a composition of matter of Claim 32.
- A method of treating osteopenia, which comprises administering a composition of matter of Claim 39.